About Us

Company Overview

AbGenomics, incorporated in the state of Delaware with its headquarters in the San Francisco Bay Area, California, and a research center in Taipei, Taiwan, is a biopharmaceutical company focused on developing novel antibody therapeutics for the treatment of cancer and immune related inflammatory diseases with high unmet medical needs.

Based on immune tolerance and epitope dominance sciences, a product candidate pipeline of three novel therapeutic targets/platforms has been developed. The Company's innovation includes an immune checkpoint agonist antibody targeting PSGL-1/CD162 that regulates T cell life cycle, a gastrointestinal (GI) tumor selective antigen, and a highly differentiated, first-in-class linker for antibody-drug conjugate (ADC) products.

AbGenomics has product candidates, as First in Class and Best in Class medicines, being tested for treating T Cell mediated diseases and GI oncological diseases. Moreover, AbGenomics has built a strong patent portfolio around its therapeutic product candidates and technical platforms.

Our Mission

AbGenomics is committed to the development of innovative treatments and prevention against inflammatory/autoimmune disease and cancer. Through the advancement of our technology platforms we aim to:

Solve unmet medical needs

Create better alternatives to existing therapies for patients

Provide patients with affordable and accessible medicine